Answers are grounded in this paper and cite their sources.
Central vascular access devices in renal hemodialysis patients have critical utility; nevertheless, they are associated with increased relative mortality risk compared to arteriovenous fistulas and grafts. Appropriate flushing and catheter locking are key to minimizing complication and dysfunction risk. Observational pre-post quality improvement evaluation was undertaken to evaluate 4% tetrasodium ethylenediaminetetraacetic acid (T-EDTA) catheter lock solution in renal hemodialysis. Four percent T-EDTA was piloted as the standard catheter lock solution (replacing 4 mg gentamicin/5000 IU per mL heparin lock). There was a 6-month evaluation period following product change, with retrospective comparison to 6 months prior. Outcome measures included bleeding complications post-insertion, catheter dysfunction, and catheter-related bloodstream infections (CR-BSI). SQUIRE 2.0 checklist for quality improvement reporting was used. Sixty-four catheters (4908 catheter days) (post) and 43 catheters (4603 catheter days) (pre) were evaluated. Bleeding complications post-catheter insertion (6% post; 38% pre), catheter dysfunction (minimal pre and post), CR-BSI (0.6 per 1000 catheter days post; 0.4 per 1000 catheter days pre) were observed. For the vulnerable population dependent on renal replacement therapy via renal hemodialysis catheters, 4% T-EDTA shows promise as a catheter lock solution, given no notable increase in CR-BSI or dysfunction, and a major reduction in post-catheter insertion bleeding was observed.
No takes yet. Share an insight, caveat, or question.
McKey et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: